Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2024.10.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Romane Bonhiver und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology Laboratory, I3 Group, GIGA Research Center, University of Liege, Belgium; Division of Respirology, Department of Pediatrics, University Ho…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mucociliary Clearance, Ciliary Motility Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Mucociliary clearance (MCC) impairment can be due to mucus abnormalities or to a ciliary dysfunction, which can be innate, or secondary to infection and/or inflammation. In cystic fibrosis (CF), it is well documented that MCC is impaired due to mucus abnormalities, but little is known concerning ciliary beating. This study aimed to confirm that ciliary dyskinesia is present in CF, and if this might be innate or secondary to the chronic infection and/or inflammation. METHODS: Ciliated epithelial samples were obtained by nasal brushing from 51 CF patients, and from 30 healthy subjects. Ciliary beating was evaluated using digital high-speed videomicroscopy at 37 °C, allowing to evaluate ciliary beat frequency (CBF) and the percentage of abnormal beat pattern (CBP); this was repeated after air-liquid interface (ALI) cell culture. RESULTS: Ciliary dyskinesia was higher in CF patients than in healthy subjects, with a lower CBF and a higher percentage of abnormal CBP. Ciliary dyskinesia, already present in childhood, normalized after ALI cell culture. A chronic airway colonization did not worsen ciliary dyskinesia. CONCLUSIONS: We showed that, in CF, a ciliary dyskinesia, present from childhood, might contribute to the impaired MCC. Our results also found that the abnormal ciliary beating was not associated with a chronic infection, and resolved after ALI cell culture, suggesting that ciliary dyskinesia in CF is not innate, and might be secondary to chronic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pneumology Laboratory, I3 Group, GIGA Research Center, University of Liege, Belgium; Division of Respirology, Department of Pediatrics, University Hospital of Liege, Belgium. Electronic address: rbonhiver@uliege.be.
- Pneumology Laboratory, I3 Group, GIGA Research Center, University of Liege, Belgium; Division of Respirology, Department of Pediatrics, University Hospital of Liege, Belgium.
- Pneumology Laboratory, I3 Group, GIGA Research Center, University of Liege, Belgium.
- Division of Physiotherapy, Regional Hospital Center of Liege, Belgium.
- Biostatistics and Research Method Center, Public Health Department, University of Liege, Belgium.
- Department of ENT, University Hospital Liege, Belgium.
Zitieren
APA
Bonhiver, R., Bricmont, N., Pirotte, M., Wuidart, M. A., Monseur, J., Benchimol, L., Poirrier, A. L., Moermans, C., Calmés, D., Schleich, F., Louis, R., Seghaye, M. C., & Kempeneers, C. (2025). Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.10.003
Vancouver
Bonhiver R, Bricmont N, Pirotte M, Wuidart MA, Monseur J, Benchimol L, et al. Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.10.003
BibTeX
@article{Bonhiver2025,
author = {Bonhiver, Romane and Bricmont, Noemie and Pirotte, Maud and Wuidart, Marc-Antoine and Monseur, Justine and Benchimol, Lionel and Poirrier, Anne-Lise and Moermans, Catherine and Calmés, Doriane and Schleich, Florence and Louis, Renaud and Seghaye, Marie-Christine and Kempeneers, Céline},
title = {Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2024.10.003}
}
EUVIMED